{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Biotech Intuition","title":"Biotech Daily Top Stories - October 22, 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/7e8daa7a\"></iframe>","width":"100%","height":180,"duration":349,"description":"Daily - Oct 22, 2026 - Show Notes\nGet personalized biotech intelligence and catalyst tracking from SOZO Intuition:\nhttps://sozointuition.com\nSUMMARY\nWelcome to the SOZO biotech daily brief. Today, our lead stories cover an FDA accelerated approval for AstraZeneca in primary immunoglobulin A nephropathy, mid-stage clinical trial results from Lumen Bioscience in Clostridioides difficile, and a multi-target miniprotein discovery alliance between Astellas Pharma and AI Proteins. We also follow pipeline progress from Newron Pharmaceuticals and Thiogenesis Therapeutics, alongside new venture backing for Reju Therapeutics. Sources are in the show notes.\nCHAPTERS AND SOURCES\n00:00 - SOZO Biotech Daily Brief\n00:34 - AstraZeneca's Ultomiris Wins FDA Accelerated Approval\nUltomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A…:\nhttps://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html\n01:38 - Lumen Reports Phase 2 RePreve Results for LMN-201\nLumen's LMN-201 shows positive RePreve Phase 2 results in C. difficile 2026-10-22:\nhttps://www.lumen.bio/2026/10/22/lumen-s-lmn-201-shows-positive-re-preve-results-in-c-difficile\n02:32 - Astellas and AI Proteins Form Miniprotein Discovery Pact\nAstellas Pharma and AI Proteins enter miniprotein discovery collaboration valued at over $400 million 2026-10-21:\nhttps://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million\n03:18 - Newron Completes Phase 3 ENIGMA-TRS 1 Enrollment\nNewron completes enrollment of pivotal Phase 3 ENIGMA-TRS 1 study of evenamide 2026-10-22:\nhttps://www.newron.com/news-and-media/regulatory-news/newron-completes-enrollment-pivotal-phase-3-enigma-trs-1-study\n03:54 - FDA Clears TTI-0102 IND in Nephropathic...","thumbnail_url":"https://img.transistorcdn.com/9CRjd85JHtM1TuR9eJILKciqKkE8Zi-g-0T-xOirVCU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZGRl/OGVlNDg2NjQ1MmUx/OTMyMjcxZmY3Zjdk/N2JiYS5qcGVn.webp","thumbnail_width":300,"thumbnail_height":300}